SparkCures ID | 986 |
---|---|
Trial Phase | Phase 1 |
Enrollment | 23 Patients |
Treatments |
|
Trial Sponsors |
|
Trial Collaborators |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Inclusion Criteria:
* Proteasome inhibitor moderate resistance: Less than or equal to stable disease with prior treatment with proteasome inhibitor containing regimen at moderate doses defined as carfilzomib 27+ mg/m²/wk, bortezomib 1.3+ mg/m²/wk subcutaneously (SQ) or IV, or ixazomib 3+ mg/wk PO
Exclusion Criteria:
Please visit the ClinicalTrials.gov page for historical site information.
View CentersRead the latest news and updates on this trial.
January 14, 2019
A Phase 1 trial of the combination of Reolysin (pelareorep), Kyprolis (carfilzomib), and Opdivo (nivolumab) in relapsed multiple myeloma treated the first patient.
SparkCures is working closely with Winship Cancer Institute to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.
Learn more about how we work with trial sponsors